Abstract
Musculoskeletal metabolic diseases such as osteoporosis have become the major public health problems worldwide in our aging society. Pharmaceutical therapy is one of the approaches to prevent and treat related medical conditions. Most of the clinically used anti-osteoporotic drugs are administered systemically and have demonstrated some side effects in non-skeletal tissues. One of the innovative approaches to prevent potential adverse effects is the development of bone-targeting drug delivery technologies that not only minimizes the systemic toxicity but also improves the pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the currently available bone targeting drug delivery systems with emphasis as bone-targeting moieties, including the bonesurface- site-specific (bone formation dominant or bone resorption dominant) and cell-specific moieties. In addition, the connections of drug-bone-targeting moieties-carrier are also summarized, and the newly developed liposomes and nanoparticles are discussed for their potential use and main challenges in delivering therapeutic agents to bone tissue. As a rapid-developing biotechnology, systemic bonetargeting delivery system is promising but still in its infancy where challenges are ahead of us, including the stability and the toxicity issues, especially to fulfill the regulatory requirement to realize bench-to-bedside translation. Newly developed biomaterials and technologies with potential for safer and more effective drug delivery require multidisciplinary collaborations with preclinical and clinical scientists that are essential to facilitate their clinical applications.
Keywords: Bone-targeting, systemic drug delivery system, liposomes, nanoparticles.
Current Pharmaceutical Design
Title:Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Volume: 21 Issue: 12
Author(s): Wang Xinluan, Lai Yuxiao, Ng HueiLeng Helena, Yang Zhijun and Qin Ling
Affiliation:
Keywords: Bone-targeting, systemic drug delivery system, liposomes, nanoparticles.
Abstract: Musculoskeletal metabolic diseases such as osteoporosis have become the major public health problems worldwide in our aging society. Pharmaceutical therapy is one of the approaches to prevent and treat related medical conditions. Most of the clinically used anti-osteoporotic drugs are administered systemically and have demonstrated some side effects in non-skeletal tissues. One of the innovative approaches to prevent potential adverse effects is the development of bone-targeting drug delivery technologies that not only minimizes the systemic toxicity but also improves the pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the currently available bone targeting drug delivery systems with emphasis as bone-targeting moieties, including the bonesurface- site-specific (bone formation dominant or bone resorption dominant) and cell-specific moieties. In addition, the connections of drug-bone-targeting moieties-carrier are also summarized, and the newly developed liposomes and nanoparticles are discussed for their potential use and main challenges in delivering therapeutic agents to bone tissue. As a rapid-developing biotechnology, systemic bonetargeting delivery system is promising but still in its infancy where challenges are ahead of us, including the stability and the toxicity issues, especially to fulfill the regulatory requirement to realize bench-to-bedside translation. Newly developed biomaterials and technologies with potential for safer and more effective drug delivery require multidisciplinary collaborations with preclinical and clinical scientists that are essential to facilitate their clinical applications.
Export Options
About this article
Cite this article as:
Xinluan Wang, Yuxiao Lai, Helena HueiLeng Ng, Zhijun Yang and Ling Qin, Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review, Current Pharmaceutical Design 2015; 21 (12) . https://dx.doi.org/10.2174/1381612821666150115152841
DOI https://dx.doi.org/10.2174/1381612821666150115152841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Trifluoromethylated Derivatives on Prostaglandin E<sub>2</sub> and Thromboxane A<sub>2</sub> Production in Human Leukemic U937 Macrophages
Medicinal Chemistry Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents PACAP is Implicated in the Stress Axes
Current Pharmaceutical Design LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review
Current Pharmaceutical Design A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Functions and Mechanisms of Green Tea Catechins in Regulating Bone Remodeling
Current Drug Targets Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Double Point Modified Analogs of Vitamin D as Potent Activators of Vitamin D Receptor
Current Pharmaceutical Design Rapid Assays for Quantitating Cytokine Gene Expression Without Target Amplification
Combinatorial Chemistry & High Throughput Screening Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry